What is the recommended dosing schedule for Slynd (drospirenone 4 mg) and its contraindications, and what alternative progesterone regimens are suggested for endometrial protection?

Slynd (Drospirenone 4 mg) Dosing and Clinical Guidance

Slynd is dosed as 24 white tablets containing 4 mg drospirenone taken daily, followed by 4 green inactive tablets, for a continuous 28-day cycle without interruption between packs 1.

Dosing Schedule

The FDA-approved regimen consists of:

• 24 consecutive days of 4 mg drospirenone (white tablets)
• 4 consecutive days of inactive placebo tablets (green tablets)
• Start the next pack immediately without a break

When to Start

Slynd can be initiated at any time 2. However, backup contraception requirements depend on timing:

• If started within 1 day of menses onset: no backup needed
• If started >1 day after menses: abstain from intercourse or use barrier methods for 7 days 2

This differs from other progestin-only pills (norethindrone/norgestrel) which only require 2 days of backup contraception, reflecting drospirenone's unique pharmacology.

Absolute Contraindications

Slynd is contraindicated in the following conditions 1:

• Renal impairment (due to hyperkalemia risk from antimineralocorticoid activity)
• Adrenal insufficiency (cannot compensate for mineralocorticoid effects)
• Presence or history of progestin-sensitive cancers
• Liver tumors (benign or malignant) or hepatic impairment
• Undiagnosed abnormal uterine bleeding

Critical Safety Monitoring

Check serum potassium levels during the first treatment cycle in patients on chronic medications that increase potassium (ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs, heparin) 1. Drospirenone's antimineralocorticoid activity distinguishes it from other progestins and creates unique hyperkalemia risk.

Alternative Progesterone Regimens for Endometrial Protection

When endometrial protection is needed (e.g., in hormone replacement therapy), multiple evidence-based progestin regimens exist 3:

Continuous Daily Regimens:

• Medroxyprogesterone acetate (MPA): 2.5 mg daily
• Micronized progesterone (MP): 100 mg daily
• Norethindrone acetate: 0.35 mg daily
• Drospirenone: 3 mg daily (note: lower dose than Slynd)
• Levonorgestrel: 0.075 mg daily

Cyclic Regimens (10-12 days per month):

• MPA: 5 mg for 10-12 days/month
• Micronized progesterone: 200 mg for 10-12 days/month 4
• Norethindrone acetate: 5 mg for 10-12 days/month

Preferred Options by Clinical Context

For young women with iatrogenic premature ovarian insufficiency, micronized progesterone is the first-choice progestin when combined with transdermal estradiol 4. Sequential regimens require:

• 200 mg oral or vaginal MP for 12-14 days every 28 days, OR
• 10 mg MPA for 12-14 days per month, OR
• 10 mg dydrogesterone for 12-14 days per month

Micronized progesterone demonstrates lower cardiovascular and venous thromboembolism risk compared to synthetic progestins when used cyclically 4.

For continuous combined regimens, minimum doses include:

• 1 mg norethisterone daily
• 2.5 mg MPA daily
• 5 mg dydrogesterone daily 4

Clinical Pearls and Pitfalls

Unique Pharmacology

Drospirenone has a 30-34 hour half-life, substantially longer than other progestin-only pills 5, 6. This provides forgiveness for missed pills—ovulation inhibition is maintained even after a scheduled 24-hour delay 5, 6, 7.

Bleeding Patterns

Expect variable bleeding patterns 8, 9:

• 52% achieve absence of bleeding/spotting with continuous use
• 44% experience unscheduled bleeding, more common in older patients with higher BMI
• Women with longer baseline menstrual cycles are more likely to have scheduled bleeding during the hormone-free interval 8
• Breakthrough bleeding is the most common reason for discontinuation (25% discontinuation rate) 9

Special Populations

In adolescents with endometriosis, continuous Slynd (skipping placebo pills) demonstrates good efficacy: 67% report reduced pain, though breakthrough bleeding remains problematic 9. This is particularly valuable since 56% of these patients have contraindications to estrogen-containing therapy 9.

Avoid Progestins with Anti-Androgenic Effects

In women with iatrogenic premature ovarian insufficiency who may have low testosterone and diminished libido, avoid progestins with anti-androgenic properties as they can worsen hypoandrogenism 4. While drospirenone has anti-androgenic activity, this must be weighed against individual patient factors.

Drug Interactions

Strong CYP3A4 inducers (phenytoin, carbamazepine, rifampin, St. John's wort) reduce drospirenone effectiveness 2, 1. Use backup contraception or alternative methods when these medications are prescribed.